Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
1
10
2019
pubmed:
1
10
2019
medline:
11
10
2019
Statut:
ppublish
Résumé
Glucagonoma is a rare type of functional pancreatic neuroendocrine tumor that is characterized by distinctive clinical manifestations; among these, necrolytic migratory erythema represents the hallmark clinical sign of glucagonoma syndrome and is usually presented as the initial complaint of patients. A 30-year-old male patient was admitted to our hospital with a complaint of diffuse erythematous ulcerating skin rash for more than 10 months. He also complained of hyperglycemia and a weight loss of 15 kg in those months. This patient underwent a contrast-enhanced computed tomography scan which showed a pancreatic body mass measuring approximately 6 cm with low density accompanied by partial calcification in plain scanning images and uneven enhancement in strengthening periods. In addition, laboratory tests indicated elevated fasting blood glucagon (1109 pg/mL, normal range: 50-150 pg/mL) levels. Glucagonoma syndrome was ultimately diagnosed in clinical. Spleen-preserving distal pancreatectomy was conducted and postoperative pathology revealed the presence of glucagonoma. The patient recovered uneventfully with the glucagonoma syndrome disappeared soon after surgery, and the postoperative plasma glucagon decreased to a normal level. Follow-up showed no recurrence for 5 years since the surgery. The treatment of glucagonoma should be directed according to the stage at which the disease is diagnosed. Surgery is currently the only method available to cure the tumor, although medications are given to patients who present with advanced glucagonoma and who are not candidates for operation. Multidisciplinary therapy and multimodality treatment are advised, although these have been systematically evaluated to a lesser degree.
Identifiants
pubmed: 31567941
doi: 10.1097/MD.0000000000017037
pii: 00005792-201909200-00011
pmc: PMC6756711
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e17037Références
Oncol Lett. 2015 Aug;10(2):1113-1116
pubmed: 26622635
Ann Surg Oncol. 2012 Dec;19(13):4270-7
pubmed: 22752376
Chin J Cancer. 2013 Jun;32(6):312-24
pubmed: 23237225
Lancet. 1974 Jul 6;2(7871):1-5
pubmed: 4134714
Annu Rev Med. 2015;66:1-16
pubmed: 25341008
Proc R Soc Med. 1971 Dec;64(12):1197-8
pubmed: 5131260
Dtsch Med Wochenschr. 2011 Jun;136(24):1319-30
pubmed: 21656454
World J Surg. 2000 Nov;24(11):1353-60
pubmed: 11038206
Rare Tumors. 2009 Jul 22;1(1):e6
pubmed: 21139900
Gland Surg. 2018 Feb;7(1):20-27
pubmed: 29629316
World J Gastroenterol. 2013 Mar 7;19(9):1458-65
pubmed: 23539545
Cancer. 2008 Sep 1;113(5):921-9
pubmed: 18618495
Int J Dermatol. 2016 Nov;55(11):1272-1274
pubmed: 26679842
Gland Surg. 2014 Nov;3(4):258-75
pubmed: 25493258
Clin Endocrinol (Oxf). 2011 May;74(5):593-8
pubmed: 21470282
Int J Surg. 2014;12 Suppl 1:S123-5
pubmed: 24859404
N Engl J Med. 2011 May 12;364(19):1871-2; author reply 1873-4
pubmed: 21561357
Surg Endosc. 2007 Apr;21(4):579-86
pubmed: 17180287
Am Surg. 2002 Aug;68(8):660-5; discussion 665-6
pubmed: 12206598
Dig Surg. 2010 Aug;27(3):197-204
pubmed: 20571266
N Engl J Med. 1966 Jun 23;274(25):1408-13
pubmed: 4286757
Clin Nucl Med. 2015 Nov;40(11):877-9
pubmed: 26204206
Lancet Oncol. 2014 Jan;15(1):e8-21
pubmed: 24384494
Arch Surg. 2011 Aug;146(8):953-8
pubmed: 21844436
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022
pubmed: 27422767
Surg Today. 2011 Oct;41(10):1332-43
pubmed: 21922354
Onco Targets Ther. 2014 Aug 14;7:1449-53
pubmed: 25152626
Am J Med Sci. 2001 May;321(5):306-20
pubmed: 11370794
Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):473-5
pubmed: 15313692